• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Urban Health ‘Accelerator’ Aims to Transform Cardiovascular Population Health Globally
ihadmin2May 22, 2023May 22, 2023GenevaThe CARDIO4Cities Accelerator by Novartis Foundation and IntraHealth International aims to replicate the successful CARDIO4Cities approach in 30 major cities within three years to transform cardiovascular population health and equity globally.Results of initial programs in S ão Paulo, Dakar and Ulaanbaatar show the cost-effective approach averted up to 13% of strokes and 12% of heart attacks during implementation.Experts say public-private partnerships are key to address the growing burden of cardiovascular disease, the world ’s leading cause of death,according to the World Health O...
Source: IntraHealth International - May 22, 2023 Category: International Medicine & Public Health Authors: ihadmin2 Source Type: news

Janssen ’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
TITUSVILLE, NJ, November 4, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first impact summary for its Save Legs. Change Lives.™ Spot Peripheral Artery Disease Now multi-year initiative, designed to create urgency and action around the hidden threat of peripheral artery disease (PAD)-related amputation. In its inaugural year, Save Legs. Change Lives.™ focused on reaching Black Americans, who are up to four times more likely than white Americans to have a PAD-related amputation.1 With this critical initiative, Janssen is focused on helping those at risk of PAD through more th...
Source: Johnson and Johnson - November 4, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

What ’s the Big Deal about Data in Medtech?
Discussion, “Top 5 Things You Need to Know about the Implantable Internet of Things." Brian Chapman, partner and leader of ZS’s medtech practice of ZS, attributes today’s focus on data to the intersection of two important things: "A general recognition that understanding more and connecting actions with outcomes will provide feedback and understanding that will drive standards of care. This is not new, but as capabilities rise in data collection, aggregation, and synthesize rise, and coupled with machine learning, the promise of data in healthcare is becoming even more ...
Source: MDDI - December 20, 2019 Category: Medical Devices Authors: Daphne Allen Tags: Digital Health Source Type: news

AI and Health Care Are Made for Each Other
Artificial intelligence has the potential to radically change health care. Imagine a not too distant future when the focus shifts away from disease to how we stay healthy. At birth, everyone would get a thorough, multifaceted baseline profile, including screening for genetic and rare diseases. Then, over their lifetimes, cost-effective, minimally invasive clinical-grade devices could accurately monitor a range of biometrics such as heart rate, blood pressure, temperature and glucose levels, in addition to environmental factors such as exposure to pathogens and toxins, and behavioral factors like sleep and activity patterns...
Source: TIME: Health - October 24, 2019 Category: Consumer Health News Authors: Geralyn Miller Tags: Uncategorized Healthcare Source Type: news

February Partner Spotlight
The Texas Diabetes Prevention and Control Program Incorporates NDEP Messages and Materials in its “Get Tested Today” Campaign The Texas Diabetes Prevention and Control Program (DPCP) at the Texas Department of State Health Services administers grant-funded initiatives and contracted services to address current issues affecting people with diabetes and those at risk of getting diabetes. The Texas DPCP maintains a statewide system of quality education services for all people with diabetes and health care professionals who offer diabetes treatment and educa...
Source: National Diabetes Education Program - January 31, 2014 Category: Endocrinology Source Type: news